Ipca Laboratories Ltd share price logo

Ipca Laboratories Ltd Share Price

(IPCALAB)

Mid Cap

Healthcare Sector

₹1404.4▲0.33%

as on 04:01PM, 17 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Ipca Laboratories Ltd Performance

  • Day's Low

    Day's High

    ₹1,380.6
    Day's Price Range
    ₹1,417.8

  • 52 Week's Low

    52 Week's High

    ₹1,052
    52-Week Price Range
    ₹1,755.9
1 Month Return+ 4.26 %
3 Month Return-9.22 %
1 Year Return+ 3.85 %
Previous Close₹1,409.00
Open₹1,409.00
Volume63.96K
Upper Circuit₹1,690.80
Lower Circuit₹1,127.20
Market Cap₹35,630.22Cr

Ipca Laboratories Ltd Fundamentals

P/E Ratio

48.83

PEG Ratio

7.5

Market Cap

₹35,630.22 Cr

P/B Ratio

4.95

EPS

20.86

Dividend Yield

0.32

Sector

Pharmaceuticals

ROE

9.81

Ipca Laboratories Ltd Analyst Rating

based on 20 analysts

BUY

65.00%

Buy

20.00%

Hold

15.00%

Sell

Based on 20 analysts offering long term price targets for Ipca Laboratories Ltd. An average target of ₹1639.75

Source: S&P Global Market Intelligence

Ipca Laboratories Ltd Share analysis

Ipca Laboratories Ltd price forecast by 20 analysts

Upside of16.76%

High

₹1918

Target

₹1639.75

Low

₹900

Ipca Laboratories Ltd target price ₹1639.75, a slight upside of 16.76% compared to current price of ₹1404.4. According to 20 analysts rating.

Source: S&P Global Market Intelligence

Key events for Ipca Laboratories Ltd

  • Ipca Laboratories Reports Strong Financial Growth - 16 Apr, 2025

    Ipca Laboratories achieved 18% revenue growth in FY25, with EBITDA rising 29.8%. The company remains optimistic about future growth in chronic care and pain management segments.

  • IPCA Laboratories Shares Plummet Amid Tariff Concerns - 04 Apr, 2025

    On April 4, 2025, shares of Ipca Laboratories fell significantly due to U.S. President Trump's indication of impending tariffs on pharmaceutical imports, leading to a broader decline in the sector.

  • Ipca Laboratories Gains from Tariff Exemption News - 03 Apr, 2025

    Ipca Laboratories' promoters may be exempt from an open offer due to a stake increase. Shares surged 7% after the U.S. exempted pharmaceuticals from tariffs.

  • Ipca Laboratories Announces Facility Sale and Acquisition - 28 Mar, 2025

    Ipca Laboratories will sell its Tarapur manufacturing facility for ₹36.90 crore to optimize operations. Additionally, it plans to acquire Unichem Laboratories Ltd., Ireland, for ₹4 crore to enhance its European presence.

Insights on Ipca Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, 59.59 Cr → 248.14 Cr (in ₹), with an average increase of 30.9% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, IPCALAB stock has moved up by 5.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.9% return, outperforming this stock by 88.1%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 44.72% of holdings in Mar 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 55.1% return, outperforming this stock by 51.0%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 11.07% to 10.76% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 2.38K Cr → 2.26K Cr (in ₹), with an average decrease of 4.9% per quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 8.53% to 8.46% in Mar 2025 quarter

Ipca Laboratories Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹2,052.85Cr (-)₹2,033.03Cr (↓0.97%)₹2,092.63Cr (↑2.93%)₹2,354.90Cr (↑12.53%)₹2,245.37Cr (↓4.65%)
Net Income₹222.65Cr (-)₹2.91Cr (↓98.69%)₹198.98Cr (↑6,737.80%)₹245.44Cr (↑23.35%)₹277.33Cr (↑12.99%)
Net Profit Margin10.85% (-)0.14% (↓98.71%)9.51% (↑6,692.86%)10.42% (↑9.57%)12.35% (↑18.52%)
Value in ₹ crore
Details2021202220232024
Total Assets₹6,098.57Cr (-)₹7,539.92Cr (↑23.63%)₹8,465.49Cr (↑12.28%)₹8,682.44Cr (↑2.56%)
Total Liabilities₹1,345.85Cr (-)₹2,064.16Cr (↑53.37%)₹2,588.19Cr (↑25.39%)₹2,333.73Cr (↓9.83%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹561.43Cr (-)₹1,096.06Cr (↑95.23%)₹831.72Cr (↓24.12%)₹762.29Cr (↓8.35%)₹830.51Cr (↑8.95%)

Ipca Laboratories Ltd Index Inclusions

Nifty Healthcare

₹13,711.05

1.16 (▲157.55%)

NIFTY PHARMA

₹21,126.75

1.21 (▲252.45%)

S&P BSE 250 LargeMidCap

₹10,181.09

1.4 (▲140.44%)

S&P BSE 150 MidCap

₹14,617.27

0.6 (▲87.26%)

BSE Healthcare

₹41,697.12

0.91 (▲377.9%)

S&P BSE 400 MidSmallCap

₹10,953.51

0.53 (▲58.2%)

Nifty 500

₹21,681.55

1.3 (▲277.2%)

BSE Mid-Cap

₹41,980.48

0.56 (▲234.26%)

BSE 200

₹10,763.75

1.44 (▲152.51%)

Nifty Midcap 150

₹19,433.45

0.58 (▲112.85%)

Nifty LargeMidcap 250

₹15,053.65

1.08 (▲161.05%)

BSE 500

₹34,109.67

1.3 (▲439.36%)

Nifty MidSmallcap 400

₹18,008.90

0.54 (▲96.3%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

Ipca Laboratories Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
44.72%
0.00
Foreign Institutions
10.76%
0.00
Mutual Funds
29.63%
0.00
Retail Investors
8.46%
0.00
Others
6.43%
0.00

Ipca Laboratories Ltd Key Indicators

Details20202021202220232024
Book Value Per Share (₹)143.07185.33215.41230.27249.59
Details20202021202220232024
Earning Per Share (₹)23.8945.2935.9119.3920.86
Details20202021202220232024
Return On Equity %19.1527.0616.828.919.81
Details20202021202220232024
Return On Assets %11.518.6911.735.576.3

Ipca Laboratories Ltd Valuation

Ipca Laboratories Ltd in the last 5 years

  • Overview

  • Trends

Lowest (18.72x)

October 10, 2019

Today (48.83x)

April 17, 2025

Industry (53.02x)

April 17, 2025

Highest (65.89x)

September 25, 2024

LowHigh

Ipca Laboratories Ltd Earnings and Dividends

  • Ipca Laboratories Ltd Earnings Results

    Ipca Laboratories Ltd’s net profit jumped 37.95% since last year same period to ₹248.14Cr in the Q3 2024-2025. On a quarterly growth basis, Ipca Laboratories Ltd has generated 8.13% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Ipca Laboratories Ltd Dividends November,2024

    In the quarter ending September 2024, Ipca Laboratories Ltd has declared dividend of ₹2 - translating a dividend yield of 0.28%.

    Read More about Dividends

Ipca Laboratories Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Ipca Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

Ipca Laboratories Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Ipca Laboratories Ltd
Ipca Laboratories Ltd
BUY₹35,630.22 Cr17.35%0.58₹529 Cr₹7,705 Cr
Sanofi India Ltd
Sanofi India Ltd
BUY₹14,328.11 Cr-3.72%0.52₹602 Cr₹2,851 Cr
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
BUY₹68,648.57 Cr23.32%0.56₹3,168 Cr₹29,001 Cr
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
HOLD₹83,673.39 Cr29.91%0.64₹3,854 Cr₹19,547 Cr
Abbott India Ltd
Abbott India Ltd
BUY₹65,216.25 Cr16.36%0.53NANA
See all

About Ipca Laboratories Ltd

Ipca Laboratories is a fully integrated global pharmaceutical company, manufacturing and marketing over 350 formulations and 80 APIs in over 100 countries around the world. Established in 1949, with its original name as Indian Pharmaceutical Combine Association Limited, Ipca has 17 manufacturing units in India, producing APIs and Formulations that are approved by major drug regulatory authorities, including the US FDA, UK MHRA, South African MCC, Brazilian ANVISA and Australian TGA. Apart from native India, Ipca is also a recognized supplier of intermediates and APIs⁠—Atenolol, Chloroquine Phosphate, Furosemide, and Pyrantel Salts⁠—globally. Ipca has received accreditation from ISO 9001, Forbes Global 200 best small companies, WHOGMP, INVIMA Colombian, and German standards, making it a respected name in the pharmaceutical industry. Recently, Ipca has acquired a number of companies, namely Krebs Biochemicals and Industries Ltd., Pisgah Labs Inc., Trophic Wellness Private Ltd, Lyka Labs Limited, and M/s. Ramdev Chemical Private Limited, to further extend its presence in the global market.

Revenue: ₹2,245.37Cr as on December 2024 (Q4 24)
Net Profit: ₹277.33Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: Premchand Godha
OrganisationIpca Laboratories Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Ipca Laboratories Ltd

What is Ipca Laboratories Ltd price today?

Ipca Laboratories Ltd share price today stands at ₹1404.4, Open: ₹1409, Previous Close: ₹1409, High: ₹1417.8, Low: ₹1380.6, 52 Week High: ₹1755.9, 52 Week Low: ₹1052.

How to Buy Ipca Laboratories Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Ipca Laboratories Ltd shares

What are today's traded volumes of Ipca Laboratories Ltd?

Today's traded volume of Ipca Laboratories Ltd(IPCALAB) is 63.96K.

What is today's market capitalisation of Ipca Laboratories Ltd?

Today's market capitalisation of Ipca Laboratories Ltd(IPCALAB) is ₹35630.22Cr.

What is the 52 Week High and Low Range of Ipca Laboratories Ltd?

Ipca Laboratories Ltd (IPCALAB)
Price
52 Week High
₹1755.9
52 Week Low
₹1052

How much percentage Ipca Laboratories Ltd is down from its 52 Week High?

Ipca Laboratories Ltd (IPCALAB) share price is ₹1404.4. It is down -20.02% from its 52 Week High price of ₹1755.9

How much percentage Ipca Laboratories Ltd is up from its 52 Week low?

Ipca Laboratories Ltd (IPCALAB) share price is ₹1404.4. It is up 33.50% from its 52 Week Low price of ₹1052